Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announces the release of its financial results for Q2 2022 on August 9, 2022, after market close. A conference call will follow at 4:30 PM EDT. The company focuses on developing infectious disease vaccines and treatments for rare liver and respiratory diseases using its proprietary mRNA technologies. Notable collaborations include partnerships with Janssen Pharmaceuticals and Ultragenyx Pharmaceutical. For more information, visit www.ArcturusRx.com.
Arcturus Therapeutics (NASDAQ: ARCT) announced that its Board of Directors approved stock options for 48,200 shares to seven new employees. These options, granted under Nasdaq Rule 5635(c)(4), have an exercise price of $12.26 per share, based on the closing stock price from June 16, 2022. The options will vest over four years, with a portion vesting annually. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory conditions.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced stock option grants totaling 38,800 shares to five new employees as an inducement for their acceptance of employment. The options have an exercise price of $16.84 per share, the closing price on May 16, 2022. They will vest over four years, with 25% vesting after the first year and the remainder monthly over the next three years. This decision aligns with Nasdaq’s inducement grant exception and highlights Arcturus' ongoing commitment to attracting talent in the mRNA medicine sector.
Arcturus Therapeutics reported significant advancements in its vaccine development against COVID-19, showcasing a 54-fold and 46-fold increase in neutralizing antibodies for Omicron BA.1 and BA.2 with its booster ARCT-154. Financially, the company posted $5.2 million in revenue for Q1 2022, up from $2.1 million year-over-year. Despite this, a net loss of $51.2 million was reported. Arcturus plans to initiate a global registrational booster trial for ARCT-154 soon, supported by a solid cash position of $319.7 million.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported promising results from its Phase 1/2 booster trial for ARCT-154, showing sustained neutralizing antibody activity against SARS-CoV-2 for at least three months post-vaccination. The study involved 12 participants receiving a low-dose booster (5 mcg) after two primary doses of Comirnaty®. Results indicated a 30-fold enhancement in neutralizing antibodies against the D614G variant and 24-fold against the Beta variant at three months. Preparations for a pivotal Phase 3 booster trial have been initiated.
Summary not available.
Arcturus Therapeutics (NASDAQ: ARCT) will release its financial results for Q1 2022 on May 9, 2022, after market close. A conference call and webcast will follow at 4:30 PM EDT. The company, based in San Diego, California, focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory conditions. Key collaborations include partnerships with prominent pharmaceutical companies and institutions.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has granted stock options totaling 60,400 shares to four newly-hired employees, as approved by its Board of Directors. The options have an exercise price of $25.24 per share and will vest over four years. This grant is part of the Nasdaq Rule 5635(c)(4) inducement exception, aimed at aiding in employee recruitment. Founded in 2013 and based in San Diego, Arcturus focuses on developing messenger RNA medicines for infectious diseases and rare liver and respiratory conditions.
Arcturus Therapeutics announced positive topline data from its ongoing Phase 1/2/3 trial for ARCT-154, a self-amplifying mRNA vaccine against COVID-19. The study demonstrated 95% efficacy in preventing severe disease and 55% efficacy against symptomatic cases. Conducted in Vietnam during the Delta and Omicron variant dominance, the trial enrolled over 19,000 adults, with comparable adverse events to placebo. Following this success, ARCT-154 will advance into a pivotal booster trial, signaling a significant step for the company's mRNA platform and future vaccine development.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced that CEO Joseph Payne will participate in the "RNA Therapeutics in Rare Diseases" panel at the Cantor Fitzgerald Virtual Rare Disease Summit on March 29, 2022, at 2:45 p.m. ET. This event highlights Arcturus' commitment to RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company, based in San Diego, has a diverse pipeline of mRNA vaccine programs, including those for COVID-19 and cystic fibrosis, supported by innovative delivery technologies and strategic partnerships.